MediWound Ltd. Files Form 6-K for February 2025
Ticker: MDWD · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1593984
| Field | Detail |
|---|---|
| Company | Mediwound Ltd. (MDWD) |
| Form Type | 6-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, form-6k, foreign-private-issuer
TL;DR
MediWound Ltd. filed a 6-K on Feb 12, 2025, with a press release titled "MediWound I".
AI Summary
On February 12, 2025, MediWound Ltd. announced the issuance of a press release. The press release is titled "MediWound I". This filing is a Form 6-K, which is a report of a foreign private issuer.
Why It Matters
This filing indicates that MediWound Ltd. is providing an update or new information to the SEC as a foreign private issuer, which could contain material developments for investors.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that typically reports information already made public, such as press releases, and does not inherently signal significant new risks.
Key Numbers
- 001-36349 — Commission File Number (Identifies the specific SEC filing for MediWound Ltd.)
Key Players & Entities
- MediWound Ltd. (company) — Registrant
- February 12, 2025 (date) — Filing Date
- 001-36349 (other) — Commission File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of a foreign private issuer required to be filed with the SEC to provide information that the issuer has made or is required to make public in its home country, filed or made public with a stock exchange, or distributed to its security holders.
What is the filing date of this Form 6-K?
This Form 6-K was filed on February 12, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 42 Hayarkon Street, Yavne, 8122745, Israel.
What is the title of the press release mentioned in the filing?
The press release mentioned in the filing is titled "MediWound I".
Does MediWound Ltd. file annual reports under Form 20-F or Form 40-F?
MediWound Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to it.
Filing Stats: 378 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2025-02-12 07:05:06
Filing Documents
- zk2532706.htm (6-K) — 10KB
- exhibit_99-1.htm (EX-99.1) — 18KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001178913-25-000420.txt ( ) — 34KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __ EXPLANATORY NOTE On February 12, 2025, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers". A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022, March 31, 2023 and August 29, 2024 (Registration Nos. 333-265203, 333-268297 and 333-281843, respectively). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 12, 2025 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3 EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated February 12, 2025 entitled "MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers". 4